Galderma (U.K.) Limited has begun a review of its distribution arrangements, with the intention of moving to a sole-preferred distributor relationship.
Established distributors have been offered the opportunity to tender for the new operational model. It is anticipated the commencement date for the new arrangement will be early September 2019.
The preferred company will win a contract to service all customers who purchase Galderma products marketed under the Azzalure and Restylane brands in the United Kingdom and the Republic of Ireland.
Other distributors will continue to be able to purchase Galderma products and services, but the sole-preferred distributor will be supported to deliver a more customer-centric proposition, including enhanced levels of tailored support for healthcare professionals.
The move is in response to changes in the aesthetics industry. Growing demand is driving an increase in the number of both active injectors and products on the market, which is in turn creating demand for greater focus on quality and industry oversight.
Toby Cooper, Medical Solutions Business Unit Head, Galderma UK & Ireland said:
“More than ever, healthcare professionals need to have confidence in the quality of the outcomes they can deliver. They need a supplier they trust, providing them with products and support they know they can rely on.
“By refining our distribution model, we believe that we can enrich the overall relationship with our customers, offering healthcare professionals an enhanced level of tailored support as well as a continued, reliable supply of our products.”